Medication info
Cabalin Capsule 50 mg (Pregabalin)

Cabalin Capsule 50 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Hard capsule with a blue upper part and a white lower part filled with white or grayish-white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201702673 · Approved 2017.05.29 · Insurance code 640007130

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of epilepsy; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine should be administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to “4. Discontinuation of treatment.”) 2. Epilepsy Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of epilepsy; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication helps in treating peripheral and central neuropathic pain in adults. Additionally, it is used as an adjunctive treatment for partial seizures in epilepsy patients, effective regardless of the presence of secondary generalization. Furthermore, it is used to relieve the symptoms of fibromyalgia. It plays an important role in improving symptoms of pain and neurological disorders.

How to take

Adult dose

This medicine should be administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to “4. Discontinuation of treatment.”) 2. Epilepsy Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if there are changes in mood or depressive symptoms while taking it, you should consult a healthcare professional immediately. Do not administer if allergic to any of the ingredients, and patients with certain genetic disorders such as lactose intolerance should not take it. Diabetes patients may need to adjust the dosage of blood sugar control medications due to weight gain, and if symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients may experience increased dizziness or drowsiness when taking this medication, raising the risk of falls or accidents, so caution is necessary. Blurred vision or changes in eyesight may occur, so inform a healthcare professional if these symptoms arise. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, anxiety, so it is recommended to consult with a healthcare professional before stopping. Patients with a history of substance abuse are at higher risk of misusing this medication, so caution is needed during administration, and monitoring for signs of misuse or dependency is necessary. Patients with impaired kidney function may need dose adjustments, and caution must be taken for patients with severe heart disease. Caution is required when co-administering this medication with opiate analgesics due to the risk of central nervous system depression and the possibility of serious adverse reactions such as respiratory depression. Pregnant women are advised not to take this medication due to the risk of fetal malformations in early pregnancy, and fertile women should use effective contraception. Breastfeeding women should discuss with a healthcare professional the possibility of this medication being transmitted through breast milk, and may need to discontinue either breastfeeding or the medication. Caution is warranted when engaging in hazardous activities such as driving or operating machinery due to the potential for dizziness or drowsiness after taking the medication. In case of overdose, confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be required. Keep this medication out of reach of children and do not transfer it to another container for safety.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, sadness, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, reduced respiratory function, vomiting, abdominal distention, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, decreased oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, uterine cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, kidney failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, increased serum creatinine, decreased white blood cell count, nasopharyngitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, hypersensitivity, feeling fortunate, decreased libido, depersonalization, sexual hyperesthesia, restlessness, mood swings, emotional downturn, emotional uplift, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, impaired motor coordination, balance disorder, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory abnormalities, sensory reduction, sedation, somnolence, cognitive impairment, nystagmus, speech disorder, muscular spasms, reduced reflexes, motor abnormalities, psychomotor agitation, positional dizziness, tactile hypersensitivity, burning sensation, action tremors, syncope, stupor, hypokinesia, olfactory abnormalities, taste loss, writing disorder, diplopia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, during vibration, depth perception change in vision, strabismus, brightness of vision, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confused state, agitation, restlessness, seizures, affective disorder, drowsiness, confused state, depression, agitation, restlessness, seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Also, avoid storing it in places that are too hot or too cold, and it is recommended to keep it at room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsule with a blue upper part and a white lower part filled with white or grayish-white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.